Skip to main content

Chardan Capital Keeps Their Buy Rating on ProQR (PRQR)

Tipranks - Tipranks - Fri Mar 13, 6:58PM CDT

Chardan Capital analyst Keay Nakae maintained a Buy rating on ProQR today and set a price target of $4.00.

Claim 70% Off TipRanks Premium

According to TipRanks, Nakae is a 4-star analyst with an average return of 3.8% and a 39.80% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Arrowhead Pharmaceuticals, and ProQR.

Currently, the analyst consensus on ProQR is a Strong Buy with an average price target of $6.50.

See the top stocks recommended by analysts >>

Based on ProQR’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $2.92 million and a GAAP net loss of $11.01 million. In comparison, last year the company earned a revenue of $3.84 million and had a GAAP net loss of $8.11 million

Read More on PRQR:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).